---
title: "Biodexa Pharmaceuticals Plc (BDRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BDRX.US.md"
symbol: "BDRX.US"
name: "Biodexa Pharmaceuticals Plc"
industry: "Biotechnology"
datetime: "2026-05-19T20:27:07.046Z"
locales:
  - [en](https://longbridge.com/en/quote/BDRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BDRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BDRX.US.md)
---

# Biodexa Pharmaceuticals Plc (BDRX.US)

## Company Overview

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.biodexapharma.com](https://www.biodexapharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.31 | 111 | - | - | - |
| PB | 0.17 | 8 | 0.32 | 0.22 | 0.12 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-30T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.13 |
| Highest Target | 35.22 |
| Lowest Target | 35.22 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BDRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BDRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BDRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BDRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**